Immunome Stock (NASDAQ:IMNM)

Forecast Revenue Ownership Financials Chart

Previous Close

$9.24

52W Range

$8.97 - $30.96

50D Avg

$11.23

200D Avg

$13.38

Market Cap

$583.60M

Avg Vol (3M)

$834.96K

Beta

1.82

Div Yield

IMNM Company Profile

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 02, 2020

Website

IMNM Performance

IMNM Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$14.02M	-	-
Operating Income	$-109.53M	$-36.90M	$-25.20M
Net Income	$-106.81M	$-37.51M	$-24.47M
EBITDA	$-108.80M	$-36.27M	$-24.70M
Basic EPS	$-5.38	$-3.09	$-2.12
Diluted EPS	$-5.38	$-3.09	$-2.12

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
MLYS	Mineralys Therapeutics, Inc.
MOLN	Molecular Partners AG
MNOV	MediciNova, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
ADAG	Adagene Inc.
ANAB	AnaptysBio, Inc.
INAB	IN8bio, Inc.
RZLT	Rezolute, Inc.
CELC	Celcuity Inc.
CSBR	Champions Oncology, Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
AVTE	Aerovate Therapeutics, Inc.
GANX	Gain Therapeutics, Inc.
IKNA	Ikena Oncology, Inc.
ANTX	AN2 Therapeutics, Inc.
LTRN	Lantern Pharma Inc.